Volociximab

Drug Overview

Volociximab (also known as M200) is an investigational, chimeric monoclonal antibody designed to inhibit angiogenesis (the formation of new blood vessels). It specifically targets and binds to the α5β1  integrin, a protein found on the surface of endothelial cells (the cells lining blood vessels) that are actively growing. This integrin is highly expressed during the formation of new vessels that tumors need to grow and spread, but it is largely absent from mature, stable blood vessels.

In the clinical landscape of March 2026, volociximab remains an investigational agent. It was developed to provide a more targeted approach to anti-angiogenesis than broader inhibitors like bevacizumab. By blocking the  α5β1  pathway, volociximab aims to “starve” the tumor of its blood supply, leading to tumor growth inhibition and potentially increasing the effectiveness of other chemotherapy agents.

• Generic Name: Volociximab.
• Code Name: M200.
• Drug Class: Monoclonal Antibody; Anti-angiogenic Agent; Integrin Inhibitor.
• Mechanism: Inhibition of  α5β1  integrin, leading to apoptosis of tumor-associated endothelial cells.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, volociximab is not FDA-approved. It has been evaluated in Phase 1 and Phase 2 clinical trials across various solid tumors but has not yet reached a pivotal Phase 3 trial for commercial approval.

What Is It and How Does It Work? (Mechanism of Action)

Volociximab is designed to disrupt the specific “handshake” between tumor cells and the blood vessels they recruit.

1. Targeting the α5β1 Integrin

Integrins are “glue-like” proteins that help cells stick to their surroundings and send survival signals. The  α5β1 integrin is a specific subtype that binds to fibronectin in the extracellular matrix.

• Selective Inhibition: This specific integrin is a hallmark of neovascularization (new vessel growth). Volociximab binds to this integrin, preventing it from interacting with fibronectin.
• Signal Disruption: Without this interaction, the new blood vessel cells lose their “anchor” and their survival signals.

2. Induction of Endothelial Cell Apoptosis

When the  α5β1  integrin is blocked by volociximab, the endothelial cells that make up the new tumor blood vessels undergo programmed cell death (apoptosis).

• Vascular Collapse: As these cells die, the new blood vessels collapse.
• Tumor Starvation: The tumor is deprived of the oxygen and nutrients it needs to expand, which can lead to a state of tumor dormancy or regression.
• Metastatic Inhibition: By preventing the formation of new vessels, volociximab may also reduce the pathways available for cancer cells to travel to other parts of the body.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for volociximab.

Clinical research through 2026 has explored its potential in several difficult-to-treat solid tumors:

• Advanced Solid Tumors: Early trials established the safety and pharmacokinetics of the drug in patients with various advanced cancers.
• Metastatic Melanoma: Evaluated as a single agent and in combination with chemotherapy (like dacarbazine).
• Advanced Pancreatic Cancer: Investigated in combination with gemcitabine.
• Ovarian and Peritoneal Cancer: Studied as a single agent for patients with platinum-resistant disease.
• Non-Small Cell Lung Cancer (NSCLC): Explored in combination with standard chemotherapy regimens.

Dosage and Administration Protocols

As an investigational drug, volociximab dosing is strictly managed within clinical trials.

Clinical Efficacy and Research Results

The clinical journey of volociximab has provided valuable insights into integrin-targeted therapy, though it has faced challenges in achieving late-stage success.

• Phase 2 Melanoma Results: In a study of patients with metastatic melanoma, volociximab as a single agent showed that it could stabilize the disease in a portion of patients, although the “objective response rate” (tumor shrinkage) was relatively low.
• Pancreatic Cancer Combination: Trials combining volociximab with gemcitabine showed that the combination was safe and tolerable, with some evidence of prolonged stable disease in advanced cases.
• Ovarian Cancer Activity: In platinum-resistant ovarian cancer, some patients experienced long periods of disease stabilization, suggesting the drug might work better as a “cytostatic” agent (keeping cancer from growing) rather than a “cytotoxic” agent (killing it outright).

Safety Profile and Side Effects

Volociximab is generally considered to have a manageable safety profile, especially when compared to traditional chemotherapy.

Common Side Effects (>15%):

• Fatigue: The most frequently reported systemic side effect.
• Nausea and Vomiting: Usually mild to moderate.
• Infusion-Related Reactions: Fever, chills, or headache shortly after the infusion.
• Peripheral Edema: Swelling of the hands, ankles, or feet.

Specific Anti-angiogenic Risks:

• Hypertension: High blood pressure, a common “class effect” of drugs that target blood vessels.
• Proteinuria: The presence of protein in the urine, requiring regular monitoring.
• Bleeding/Thrombosis: A potential risk of increased bleeding or blood clots, although this was less frequent with volociximab than with some other anti-angiogenic drugs.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, volociximab is used to study “Vascular Stem Cell Niches.” Researchers are investigating how the  α5β1  integrin regulates the behavior of Endothelial Progenitor Cells—the stem cells that form new blood vessels. By using volociximab to block these signals, scientists can better understand how to prevent cancer from “recruiting” these stem cells. In 2026, there is also research into using volociximab to study “Tissue Engineering.” Since the drug blocks the formation of new vessels, it is used as a tool to study how to promote healthy vessel growth in regenerative therapies by understanding the exact signals that volociximab inhibits.

Disclaimer: These findings regarding volociximab, α5β1 integrin, and vascular niche biology are still evolving and are not yet applicable to practical or professional clinical scenarios. While the antibody clearly inhibits angiogenesis and can illuminate endothelial/progenitor-cell signaling, claims of direct stem-cell niche optimization or promotion of healthy vessel growth remain exploratory and should be interpreted cautiously.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Blood Pressure Monitoring: Baseline blood pressure must be established and monitored throughout treatment.
• Urinalysis: To check for proteinuria before each dose.
• Imaging: Baseline CT or MRI scans to establish a starting point for measuring the tumor.

“Do’s and Don’ts” List:

• DO report any sudden or severe headaches or changes in vision, which could be signs of high blood pressure.
• DO keep your bi-weekly infusion appointments, as the drug’s effectiveness depends on maintaining a steady level in the blood.
• DON’T ignore any new swelling in your legs or shortness of breath, as these should be evaluated by your oncology team.
• DON’T undergo major surgery while receiving volociximab without consulting your oncologist, as anti-angiogenic drugs can interfere with wound healing.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Volociximab (M200) is an investigational agent and is not approved by the U.S. FDA for any indication. Access is limited exclusively to registered clinical trials. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.